Preoperative Administration of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers: Do We Have Enough “VISION” to Stop It?

(Abstracted from Anesthesiology, 126(1):1–3, 2017) There is significant controversy regarding administration of angiotensin-converting enzyme inhibitors (ACEIs) as well as angiotensin II receptor blockers (ARBs). This editorial comments on the study by Roshanov et al1 (“Withholding Versus Continuing Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Before Noncardiac Surgery: An Analysis of the Vascular events In noncardiac Surgery patIents cOhort evaluatioN Prospective Cohort”), which examined the large multinational, prospective Vascular events In noncardiac Surgery patIents cOhort evaluatioN (VISION) trial to assess risk-adjusted associations of ACEI/ARB administration versus withholding the drugs within the 24 hours preceding noncardiac surgery.
Source: Survey of Anesthesiology - Category: Anesthesiology Tags: Preoperative and Postoperative Care Source Type: research